A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy

A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study

(2017) U. Pelzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

(2009) Joanna M. Brell et al.   ONCOLOGY

Literature Review October-December 2008

(2009) Kevin Carroll et al.   PHARMACEUTICAL STATISTICS

Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study

(2009) Uwe Pelzer et al.   Oncology Research and Treatment

Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer

(2008) Henry Q. Xiong et al.   CANCER

Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

(2008) Seong Yoon Yi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral, Small-Molecule Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor AZD6244 (ARRY-142886) in Patients With Advanced Cancers

(2008) Alex A. Adjei et al.   JOURNAL OF CLINICAL ONCOLOGY

Oral mTOR Inhibitor Everolimus in Patients With Gemcitabine-Refractory Metastatic Pancreatic Cancer

(2008) Brian M. Wolpin et al.   JOURNAL OF CLINICAL ONCOLOGY